New pill shows promise for stubborn blood disorder
NCT ID NCT03395210
Summary
This study tested a new oral medication called PRN1008 (rilzabrutinib) for adults with immune thrombocytopenia (ITP), a condition causing dangerously low platelet counts. It involved about 86 people whose previous treatments had stopped working or didn't help enough. The main goals were to find a safe and effective dose and to see if the pill could raise and maintain platelet levels over 24 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center- Site Number : 1099
Boston, Massachusetts, 02215, United States
-
Bleeding and Clotting Disorders Institute- Site Number : 1087
Peoria, Illinois, 61614-2868, United States
-
Investigational Site Number : 101
Clayton, Victoria, 3168, Australia
-
Investigational Site Number : 102
Woolloongabba, Queensland, 4102, Australia
-
Investigational Site Number : 103
Perth, Western Australia, 6005, Australia
-
Investigational Site Number : 104
Sydney, New South Wales, 2139, Australia
-
Investigational Site Number : 105
Canberra, Australian Capital Territory, 2605, Australia
-
Investigational Site Number : 106
Parkville, Victoria, 3050, Australia
-
Investigational Site Number : 1161
Toronto, Ontario, M5B 1W8, Canada
-
Investigational Site Number : 1162
Montreal, Quebec, H3A 1A1, Canada
-
Investigational Site Number : 211
Varna, 9010, Bulgaria
-
Investigational Site Number : 213
Pleven, 5800, Bulgaria
-
Investigational Site Number : 214
Sofia, 1431, Bulgaria
-
Investigational Site Number : 431
Brno, 62500, Czechia
-
Investigational Site Number : 432
Prague, 12808, Czechia
-
Investigational Site Number : 433
Hradec Králové, 50005, Czechia
-
Investigational Site Number : 434
Ostrava - Poruba, 70852, Czechia
-
Investigational Site Number : 541
Grålum, 1714, Norway
-
Investigational Site Number : 542
Bergen, N-5021, Norway
-
Investigational Site Number : 727
Rotterdam, 3015 GD, Netherlands
-
Investigational Site Number : 728
The Hague, 2545 CH, Netherlands
-
Investigational Site Number : 980
London, London, City of, W12 0HS, United Kingdom
-
Investigational Site Number : 981
Leicester, Leicestershire, LE1 5WW, United Kingdom
-
Investigational Site Number : 983
London, London, City of, E1 2ES, United Kingdom
-
Investigational Site Number : 984
Birmingham, B15 2GW, United Kingdom
-
Massachusetts General Hospital Cancer Center- Site Number : 1092
Boston, Massachusetts, 02114-2603, United States
-
Mid Michigan Medical Center- Site Number : 1086
Midland, Michigan, 48670, United States
-
New York Presbyterian Hospital/Weill Cornell Medical Center- Site Number : 1097
New York, New York, 10021, United States
-
Pitt County Memorial Hospital- Site Number : 1095
Greenville, North Carolina, 27834, United States
-
RCCA MC LLC- Site Number : 1091
Bethesda, Maryland, 20817-1915, United States
-
Seattle Cancer Care Alliance Site Number : 1098
Seattle, Washington, 98109-4405, United States
Conditions
Explore the condition pages connected to this study.